139 related articles for article (PubMed ID: 36902191)
1. Prediction Model with
Nishida N; Ohashi J; Suda G; Chiyoda T; Tamaki N; Tomiyama T; Ogasawara S; Sugiyama M; Kawai Y; Khor SS; Nagasaki M; Fujimoto A; Tsuchiura T; Ishikawa M; Matsuda K; Yano H; Yoshizumi T; Izumi N; Hasegawa K; Sakamoto N; Mizokami M; Tokunaga K
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902191
[TBL] [Abstract][Full Text] [Related]
2. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yang HI; Sherman M; Su J; Chen PJ; Liaw YF; Iloeje UH; Chen CJ
J Clin Oncol; 2010 May; 28(14):2437-44. PubMed ID: 20368541
[TBL] [Abstract][Full Text] [Related]
3. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
4. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B.
Zhang T; Zhang G; Deng X; Zeng J; Jin J; Zeping H; Wu M; Zheng R
Radiology; 2021 Nov; 301(2):350-359. PubMed ID: 34427463
[TBL] [Abstract][Full Text] [Related]
5. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
6. Blood gene signature for early hepatocellular carcinoma detection in patients with chronic hepatitis B.
Omar H; Lim CR; Chao S; Lee MM; Bong CW; Ooi EJ; Yu CG; Tan SS; Abu Hassan MR; Menon J; Muthukaruppan R; Singh M; Nik Abdullah NA; Ooi BP; Ding RP; Low EJ; Tan F; Novak D; Harris DF; Yang H; Merican I; Liew CC
J Clin Gastroenterol; 2015 Feb; 49(2):150-7. PubMed ID: 25569223
[TBL] [Abstract][Full Text] [Related]
7. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.
Lin YJ; Lee MH; Yang HI; Jen CL; You SL; Wang LY; Lu SN; Liu J; Chen CJ
PLoS One; 2013; 8(4):e61448. PubMed ID: 23613855
[TBL] [Abstract][Full Text] [Related]
8. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study.
Zhu YF; Tan YF; Xu X; Zheng JL; Zhang BH; Tang HR; Yang JY
Medicine (Baltimore); 2019 Dec; 98(50):e18319. PubMed ID: 31852119
[TBL] [Abstract][Full Text] [Related]
9. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
10. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
11. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
Tang Y; Zhang Y; Hu X
Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
[TBL] [Abstract][Full Text] [Related]
13. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
[TBL] [Abstract][Full Text] [Related]
15. A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
Zhu L; Li T; Ma X; Qiu Y; Ma X; Lin Y; Han L; Qin C
Sci Rep; 2017 Aug; 7(1):8954. PubMed ID: 28827721
[TBL] [Abstract][Full Text] [Related]
16. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
[TBL] [Abstract][Full Text] [Related]
17. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
18. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
[TBL] [Abstract][Full Text] [Related]
19. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
20. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.
El-Serag HB; Kanwal F; Davila JA; Kramer J; Richardson P
Gastroenterology; 2014 May; 146(5):1249-55.e1. PubMed ID: 24462733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
